Cenetron Announces Implementation of STARLIMS Laboratory Information Management System for Global Clinical Trials
Key features include advanced Web-based Architecture; Compliance with FDA 21 CFR part 11 Guidelines.
(PRWEB) January 23, 2008 -- Cenetron Diagnostics, Ltd., a leading Central Laboratory that specializes in molecular diagnostics, announced today that it has implemented the latest version of the STARLIMS® Laboratory Information Management System for global clinical trials. STARLIMS serves as an enterprise-wide system to build and track clinical trial collection kits, manage and track specimens, manage laboratory testing workflows, create user-defined laboratory reports and manage study-specific databases. The advanced security, data integrity, and audit trail capabilities of STARLIMS enable Cenetron to meet the stringent requirements of its pharmaceutical clients--for timely reports, for data transfers of absolute quality and accuracy, and for full compliance with FDA 21CFR part 11 guidelines.
"The implementation of STARLIMS is an important milestone in Cenetron's history," said Dwight DuBois, MD, Cenetron's President. "We are able to meet and exceed FDA and sponsor requirements with enormous flexibility. STARLIMS is able to handle complex data sets generated from molecular testing with traceability, accuracy, and clarity. STARLIMS' scalability and versatility are also important, allowing us to add functionalities as our business grows. Our team is currently completing testing of another module that allows the storage, retrieval, and analysis of DNA sequencing data.
"A leading provider of central laboratory services for clinical trials and other pharmaceutical applications, Cenetron is clearly committed to innovation in every aspect of lab automation, and STARLIMS has been part of that strategy. We are delighted to see that our long-term collaboration has brought important benefits to Cenetron: full regulatory compliance, streamlining of lab process, and integration with a wide range of processes," said Ed Krasovec, Director of Clinical Operations at STARLIMS. "A series of other important players in the clinical space are implementing our solutions, and our presence in clinical trial, health care, and public health labs is growing at a tremendous rate. In large part, this reflects the success of STARLIMS V10--an entirely web-based LIMS that offers powerful out-of-the-box capabilities for regulatory compliance; an unparalleled suite of tools and wizards specifically designed for clinical trial processes; and universal access to data via standard browsers."
About Cenetron
Cenetron Diagnostics is a premiere provider of molecular laboratory services, providing support for anti-viral and oncology drug development programs, and pharmacogenomics. Founded in 1995, Cenetron has supported pivotal global trials in North and South America, Europe, Africa and the Pacific Rim. Cenetron's client list includes leading pharmaceutical clients in the United States and Europe. For further information visit www.cenetron.com
About STARLIMS
STARLIMS Technologies Ltd. (NASDAQ: LIMS) is a leading provider of laboratory information management systems (LIMS), with over 20 years of LIMS experience. The company's flagship product, STARLIMS®, improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities. STARLIMS software is used for quality assurance and control, testing and monitoring, and research and development in government, manufacturing and life sciences organizations. With operations in the United States, Canada, the United Kingdom, Israel and Hong Kong, the company serves over 500 organizations in 40 countries. Please see www.starlims.com for more information.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SGFsZi1aZXRhLVpldGEtU3VtbS1Mb3ZlLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.